Glenmede Trust’s National Vision EYE Stock Holding History

Glenmede Trust’s Portfolio EYE Stock Details EYE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-225	Closed	-$5	–	3047
2019 Q3	$5	Buy	+225	New	+$6.55K	﹤0.01%	2624

Other funds holding EYE

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Glenmede Trust's EYE Position: Q4 2019 in Review

Glenmede Trust sold out of National Vision (EYE) in Q4 2019, closing a stake of 225 shares — an estimated $5 sold.

Glenmede Trust first reported a position in EYE in Q3 2019 and held it in 1 quarter. The position peaked at $5 in Q3 2019. 156 funds tracked by Wall St. Rank hold EYE as of Q4 2019.

Glenmede Trust reported no remaining National Vision position as of Q4 2019 after selling out during the quarter.
Glenmede Trust sold 225 National Vision shares in Q4 2019, an estimated $5.
Glenmede Trust first reported a position in National Vision in Q3 2019 and held it in 1 quarter.
Glenmede Trust's National Vision position peaked at $5 in Q3 2019.
156 funds tracked by Wall St. Rank held National Vision as of Q4 2019.

Based on Glenmede Trust's 13F filing for Q4 2019, filed 12 Feb 2020.